Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.48 USD | +1.64% | -2.36% | +12.22% |
04-25 | Sector Update: Health Care Stocks Decline Late Afternoon | MT |
04-25 | Sector Update: Health Care | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 242.1 | 444.7 | 299.8 | 92.78 | 175.5 | 948.5 | - | - |
Enterprise Value (EV) 1 | 237.3 | 430.4 | 299.8 | 92.78 | 175.5 | 948.5 | 948.5 | 948.5 |
P/E ratio | -3.59 x | -8.11 x | -5.03 x | -0.48 x | -2.35 x | -5.77 x | -13.8 x | 124 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 2.06 x | 3.22 x | 2.3 x | - | 1.65 x | 4.72 x | 4.09 x | 3.42 x |
EV / Revenue | 2.06 x | 3.22 x | 2.3 x | - | 1.65 x | 4.72 x | 4.09 x | 3.42 x |
EV / EBITDA | -5.13 x | -9.46 x | -4.7 x | - | -5.06 x | -8.59 x | -21.5 x | 29.5 x |
EV / FCF | -4.72 x | - | - | - | -3.8 x | -8.03 x | -16.6 x | 74.7 x |
FCF Yield | -21.2% | - | - | - | -26.3% | -12.4% | -6.01% | 1.34% |
Price to Book | 1.51 x | 3.22 x | - | - | -1.18 x | 1.86 x | 2.07 x | 1.95 x |
Nbr of stocks (in thousands) | 69,565 | 74,119 | 76,486 | 79,296 | 79,395 | 382,461 | - | - |
Reference price 2 | 3.480 | 6.000 | 3.920 | 1.170 | 2.210 | 2.480 | 2.480 | 2.480 |
Announcement Date | 20-02-10 | 21-02-10 | 22-02-17 | 23-02-14 | 24-02-28 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 117.2 | 138.1 | 130.6 | - | 106.3 | 201 | 232.2 | 277.5 |
EBITDA 1 | -47.23 | -47.02 | -63.81 | - | -34.66 | -110.5 | -44.17 | 32.2 |
EBIT 1 | -51.84 | -51.04 | -67.46 | - | -76.6 | -154.6 | -85.95 | -23.2 |
Operating Margin | -44.22% | -36.94% | -51.66% | - | -72.03% | -76.93% | -37.02% | -8.36% |
Earnings before Tax (EBT) 1 | -66.7 | -54.1 | -63.66 | - | -74.2 | -161.3 | -69.4 | 9 |
Net income 1 | -64.79 | -53.02 | -59.24 | -190.1 | -74.66 | -161.3 | -69.4 | 9 |
Net margin | -55.26% | -38.38% | -45.36% | - | -70.21% | -80.26% | -29.89% | 3.24% |
EPS 2 | -0.9700 | -0.7400 | -0.7800 | -2.430 | -0.9400 | -0.4300 | -0.1800 | 0.0200 |
Free Cash Flow 1 | -51.32 | - | - | - | -46.12 | -118 | -57.05 | 12.7 |
FCF margin | -43.77% | - | - | - | -43.37% | -58.74% | -24.57% | 4.58% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 39.44% |
FCF Conversion (Net income) | - | - | - | - | - | - | - | 141.11% |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 20-02-10 | 21-02-10 | 22-02-17 | 23-02-14 | 24-02-28 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 28.5 | 38.26 | 26.5 | - | 27.67 | 25.37 | 28.19 | 46 | 48.2 | 51.57 | 55.27 | 51.4 |
EBITDA 1 | -18.72 | -10.35 | - | - | -8.369 | -10.14 | -7.525 | -34.57 | -31.83 | -24.97 | -19.07 | -16.8 |
EBIT 1 | -19.61 | -11.26 | - | - | -17.45 | -21.17 | -21.39 | -46.9 | -42.9 | -35.5 | -29.3 | -32.4 |
Operating Margin | -68.8% | -29.42% | - | - | -63.07% | -83.46% | -75.87% | -101.96% | -89% | -68.84% | -53.02% | -63.04% |
Earnings before Tax (EBT) 1 | -15.26 | -10.24 | - | - | -16.74 | -20.95 | -19.94 | -45.5 | -43.6 | -38.5 | -33.8 | - |
Net income 1 | -13.84 | -9.429 | - | -16.84 | -17.04 | -21 | -19.78 | -45.5 | -43.6 | -38.6 | -33.8 | - |
Net margin | -48.57% | -24.64% | - | - | -61.59% | -82.77% | -70.16% | -98.91% | -90.46% | -74.85% | -61.16% | - |
EPS 2 | -0.1800 | -0.1200 | - | -0.2100 | -0.2200 | -0.2700 | -0.2500 | -0.1200 | -0.1100 | -0.1000 | -0.0900 | - |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 21-11-08 | 22-02-17 | 22-05-05 | 23-05-09 | 23-08-08 | 23-11-07 | 24-02-28 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | 4.82 | 14.3 | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | -51.3 | - | - | - | -46.1 | -118 | -57.1 | 12.7 |
ROE (net income / shareholders' equity) | -57.4% | -14.9% | - | - | - | -45.9% | -13.4% | 1.8% |
ROA (Net income/ Total Assets) | -22.8% | - | - | - | -20.9% | -30.1% | -9.5% | 1.3% |
Assets 1 | 284.2 | - | - | - | 356.7 | 535.9 | 730.5 | 692.3 |
Book Value Per Share 2 | 2.300 | 1.870 | - | - | -1.870 | 1.330 | 1.200 | 1.270 |
Cash Flow per Share 2 | -0.7300 | - | - | - | -0.5500 | -0.3400 | -0.1100 | 0.0900 |
Capex 1 | 2.53 | 12.7 | - | - | 2.83 | 5 | 5.27 | 7 |
Capex / Sales | 2.16% | 9.21% | - | - | 2.66% | 2.49% | 2.27% | 2.52% |
Announcement Date | 20-02-10 | 21-02-10 | 22-02-17 | 23-02-14 | 24-02-28 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.22% | 933M | |
+8.69% | 219B | |
+6.69% | 183B | |
+10.90% | 133B | |
+25.41% | 108B | |
+0.27% | 63.06B | |
+12.72% | 52.02B | |
+3.96% | 48.2B | |
+0.40% | 40.37B | |
+15.03% | 39.35B |
- Stock Market
- Equities
- LAB Stock
- Financials Standard BioTools Inc.